Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells

Biomedicine and Pharmacotherapy

Volumn 66, Issue 6, 2012, Pages 409-413

  Ori, Yaacov ^a,b   Herman Edelstein, Michal ^a,b   Zingerman, Boris ^a   Rozen Zvi, Benaya ^a   Gafter, Uzi ^a,b   Malachi, Tsipora ^a   Gafter Gvili, Anat ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Calcineurin inhibitor; DNA repair; Immunosuppressive drugs; MTOR inhibitor; Mycophenolic acid

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; BLOOD BANKS; CALCINEURIN; CARCINOGENICITY TESTS; CYCLOSPORINE; DNA REPAIR; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MYCOPHENOLIC ACID; OSMOLAR CONCENTRATION; SIROLIMUS; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84866184101     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.06.001     Document Type: Article

References (29)

1. Webster A.C., Craig J.C., Simpson J.M., Jones M.P., Chapman J.R. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007, 7:2140-2151.
2. Villeneuve P.J., Schaubel D.E., Fenton S.S., Shepherd F.A., Jiang Y., Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007, 7:941-948.
3. Vajdic C.M., McDonald S.P., McGredie M.R., Van Leeuwen M.T., Stewart J.H., Law M., et al. Cancer incidence before and after kidney transplantation. JAMA 2006, 296:2823-2831.
4. Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004, 4:905-913.
5. Kauffman H.M., Cherikh W.S., McBride M.A., Cheng Y., Hanto D.W. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transplant Int 2006, 19:607-620.
6. Buell J.F., Gross T.G., Woodle E.S. Malignancies after transplantation. Transplantation 2005, 80(2 suppl.):S254-S264.
7. Malachi T., Zevin D., Gafter U., Chagnac A., Slor H., Levi J. DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 1993, 44:385-389.
8. Herman M., Weinstein T., Korzets A., Chagnac A., Ori Y., Zevin D., et al. Effect of cyclosporine A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2000, 137:14-20.
9. Guba M., Graeb C., Jauch K.W., Geissler E.K. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004, 77:1777-1782.
10. Kaina B. DNA damage-triggered apoptosis: critical role of DNA repair, double strand breaks, cell proliferation and signaling. Biochem Phamacol 2003, 66:1547-1554.
11. Herman M., Ori Y., Chagnac A., Weinstein T., Korzets A., Zevin D., et al. DNA repair in mononuclear cells: role of serine/threonine phosphatases. J Lab Clin Med 2002, 140:255-262.
12. 2+ fluxes. J Lab Clin Med 1999, 133:362-369.
13. Ori Y., Herman M., Weinstein T., Chagnac A., Zevin D., Milo G., et al. Spontaneous DNA repair in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2004, 320:578-586.
14. Ori Y., Herman M., Chagnac A., Malachi T., Gafter U., Korzets A. Spontaneous DNA repair in human mononuclear cells is calcium-dependent. Biochem Biophys Res Commun 2005, 336:842-846.
15. Herman-Edelstein M., Rozen-Zvi B., Zingerman B., Lichtenberg S., Malachi T., Gafter U. Effect of immunosuppressive drugs on DNA repair in human peripheral blood mononuclear cells. Biomed Pharmacother 2012, 66:111-115.
16. Opelz G., Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4:222-230.
17. Dantal J., Hourmant M., Cantarovich D., Giral M., Blancho G., Dreno B., et al. Effect of long-term immunosuppression in kidney graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628.
18. Thoms K.M., Kuschal C., Oetjen E., Mori T., Kobayashi N., Laspe P., et al. Cyclosporin A, but no everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol 2011, 20:232-236.
19. Weir M.R., Mulgaonkar S., Chan L., Shidban H., Waid T.H., Preston D., et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, control spare-the-nephron trial. Kidney Int 2011, 79:897-907.
20. Cannin M.T., Nay S.L., Peña A.V., Yarosh D.B. Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J Mol Histol 2006, 37:285-291.
21. Gafter-Gvili A., Sredni B., Gal R., Gafter U., Kalechman Y. Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol 2003, 284:C1593-C1603.
22. 2+-mediated upregulation of the DNA repair enzyme DNA polymerase in human peripheral blood mononuclear cells. Eur J Biochem 1999, 164:952-959.
23. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Langman M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
24. Schena F.P., Pascoe M.D., Alberu J., del Carmen Rial M., Oberbauer R., Brennan D.C., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
25. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., Kahan B.D. Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
26. Campistol J.M., Eris J., Oberbauer R., Friend P., Hutchison B., Morales J.M., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006, 17:581-589.
27. Salgo R., Gossmann J., Schöfer H., Kachel H.G., Kuck J., Geiger H., et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a protective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010, 10:1385-1393.
28. Robson R., Cecka J.M., Opelz G., Budde M., Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005, 5:2954-3960.
29. O'Neill J.O., Edwards L.B., Taylor D.O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of transplant registry of the International Society of Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25:1186-1191.